Images |
Sources |
Experiment + Assay |
Phenotypes |
Human Diseases |
|
Fig. 1b,f
Sempou E et al. (2022)
|
Xtr Wt + barium
NF10 (in situ hybridization)
|
|
|
|
Fig. 1b,f
Sempou E et al. (2022)
|
Xtr Wt + K+ (20mM high)
NF10 (in situ hybridization)
|
|
|
|
Fig. 4a,b, e, f, k, l, m, n
Sempou E et al. (2022)
|
Xtr Wt + kcnh6 CRISPR (400pg)
NF10 (in situ hybridization)
|
|
|
|
Fig. S5 r_2 c_3
Sempou E et al. (2022)
|
Xtr Wt + kcnh6 CRISPR (400pg)
NF17 (immunohistochemistry) myod
|
|
|
|
Fig. 4b,f
Sempou E et al. (2022)
|
Xtr Wt + kcnh6 MO
NF10 (in situ hybridization)
|
|
|
|
Fig. S2 E'
Kreis J et al. (2022)
|
Xla Wt + ets2
NF10-11 (in situ hybridization)
|
|
|
|
Fig S1 D'
Kreis J et al. (2022)
|
Xla Wt + fgfr1
NF10-11 (in situ hybridization)
|
|
|
|
Fig. 3 J L N P
Kreis J et al. (2022)
|
Xla Wt + rab7a MO
NF10-11 (in situ hybridization)
|
|
|
|
FIG 2 S'
Kreis J et al. (2022)
|
Xla Wt + rab7a MO
NF17 (in situ hybridization)
|
|
|
|
Fig. J
Kreis J et al. (2021)
|
Xla Wt + ctnnb1 MO
NF10-11.5 (in situ hybridization)
|
|
|